Colonic Diverticulosis and Non-Alcoholic Fatty Liver Disease: Is There a Connection?
Abstract
:1. Introduction
2. Materials and Methods
Statistical Analysis
3. Results
4. Discussion
Limitations of the Study
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Martel, J.; Raskin, J.B. History, incidence, and epidemiology of diverticulosis. J. Clin. Gastroenterol. 2008, 42, 1125–1127. [Google Scholar] [CrossRef] [PubMed]
- Kopylov, U.; Ben-Horin, S.; Lahat, A.; Segev, S.; Avidan, B.; Carter, D. Obesity, Metabolic Syndrome and the Risk of Development of Colonic Diverticulosis. Digestion 2012, 86, 201–205. [Google Scholar] [CrossRef]
- Yeo, L.-X.; Tseng, T.-H.; Chen, W.-L.; Kao, T.-W.; Wu, L.-W.; Fang, W.-H.; Chang, Y.-W.; Peng, T.-C. Hypertension control and risk of colonic diverticulosis. Ther. Adv. Gastroenterol. 2019, 12, 1756284819855734. [Google Scholar] [CrossRef] [PubMed]
- Nagata, N.; Sakamoto, K.; Arai, T.; Niikura, R.; Shimbo, T.; Shinozaki, M.; Aoki, T.; Sekine, K.; Okubo, H.; Watanabe, K.; et al. Visceral Abdominal Obesity Measured by Computed Tomography is Associated with Increased Risk of Colonic Diverticulosis. J. Clin. Gastroenterol. 2015, 49, 816–822. [Google Scholar] [CrossRef]
- Lin, X.; Li, J.; Ying, M.; Wei, F.; Xie, X. Diabetes increases morbidities of colonic diverticular disease and colonic diverticular hemorrhage: A systematic review and meta-analysis. Am. J. Ther. 2017, 24, e213–e221. [Google Scholar] [CrossRef] [PubMed]
- Li, A.A.; Ahmed, A.; Kim, D. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Gut Liver 2020, 14, 168–178. [Google Scholar] [CrossRef] [PubMed]
- Adams, L.A.; Anstee, Q.M.; Tilg, H.; Targher, G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017, 66, 1138–1153. [Google Scholar] [CrossRef] [Green Version]
- Ma, J.; Hwang, S.-J.; Pedley, A.; Massaro, J.M.; Hoffmann, U.; Chung, R.T.; Benjamin, E.; Levy, D.; Fox, C.S.; Long, M.T. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J. Hepatol. 2017, 66, 390–397. [Google Scholar] [CrossRef] [Green Version]
- EEslam, M.; Newsome, P.N.; Sarin, S.K.; Anstee, Q.M.; Targher, G.; Romero-Gomez, M.; Zelber-Sagi, S.; Wong, V.W.-S.; Dufour, J.-F.; Schattenberg, J.M.; et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J. Hepatol. 2020, 73, 202–209. [Google Scholar] [CrossRef] [PubMed]
- Tursi, A.; Brandimarte, G.; Di Mario, F.; Lanas, A.; Scarpignato, C.; Bafutto, M.; Barbara, G.; Bassotti, G.; Binda, G.A.; Biondi, A.; et al. International Consensus on Diverticulosis and Diverticular Disease. Statements from the 3rd International Symposium on Diverticular Disease. J. Gastrointest. Liver Dis. 2020, 28, 57–66. [Google Scholar] [CrossRef]
- Strate, L.L.; Liu, Y.L.; Aldoori, W.H.; Syngal, S.; Giovannucci, E.L. Obesity Increases the Risks of Diverticulitis and Diverticular Bleeding. Gastroenterology 2009, 136, 115–122.e1. [Google Scholar] [CrossRef] [Green Version]
- Rosemar, A.; Angerås, U.; Rosengren, A. Body Mass Index and Diverticular Disease: A 28-Year Follow-Up Study in Men. Dis. Colon Rectum 2008, 51, 450–455. [Google Scholar] [CrossRef]
- Teixeira, C.; Trabulo, D.; Ribeiro, S.; Martins, C.R.; Alves, A.L.; Cremers, I.; Oliveira, A.P. Colonic diverticulosis and the metabolic syndrome: An association? Rev. EspañolaEnferm. Dig. 2017, 109, 768–771. [Google Scholar] [CrossRef] [Green Version]
- Tilg, H.; Moschen, A.R.; Szabo, G. Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 2016, 64, 955–965. [Google Scholar] [CrossRef]
- Murray, K.A.; Hoad, C.L.; Garratt, J.; Kaviani, M.; Marciani, L.; Smith, J.K.; Siegmund, B.; Gowland, P.A.; Humes, D.J.; Spiller, R.C. A pilot study of visceral fat and its association with adipokines, stool calprotectin and symptoms in patients with diverticulosis. PLoS ONE 2019, 14, e0216528. [Google Scholar] [CrossRef]
- Tursi, A.; Brandimarte, G.; Di Mario, F.; Andreoli, A.; Annunziata, M.L.; Astegiano, M.; Bianco, M.A.; Buri, L.; Cammarota, G.; Capezzuto, E.; et al. Development and Validation of an Endoscopic Classification of Diverticular Disease of the Colon: The DICA Classification. Dig. Dis. 2015, 33, 68–76. [Google Scholar] [CrossRef]
- Freckelton, J.; Holt, D.; Borsaru, A.; Gwini, S.; Croagh, D.; Moore, G. The role of body composition in diverticular disease. Int. J. Color. Dis. 2018, 33, 1299–1302. [Google Scholar] [CrossRef]
- De Cecco, C.N.; Ciolina, M.; Annibale, B.; Rengo, M.; Bellini, D.; Muscogiuri, G.; Maruotti, A.; Saba, L.; Iafrate, F.; Laghi, A. Prevalence and distribution of colonic diverticula assessed with CT colonography (CTC). Eur. Radiol. 2015, 26, 639–645. [Google Scholar] [CrossRef]
- Milovanovic, T.; Pantic, I.; Dragasevic, S.; Lugonja, S.; Dumic, I.; Rajilic-Stojanovic, M. The Interrelationship Among Non-Alcoholic Fatty Liver Disease, Colonic Diverticulosis and Metabolic Syndrome. J. Gastrointest. Liver Dis. 2021, 30, 274–282. [Google Scholar] [CrossRef]
- Kempinski, R.; Łukawska, A.; Krzyżanowski, F.; Ślósarz, D.; Poniewierka, E. Clinical outcomes of non-alcoholic fatty liver disease: Polish-case control study. Adv. Clin. Exp. Med. 2019, 28, 1615–1620. [Google Scholar] [CrossRef]
- Bae, H.J.; Kim, S.T.; Hong, S.G.; Lee, H.; Choi, H.S.; Cho, Y.-K.; Kim, T.H.; Chung, S.H. Risk Factors for Asymptomatic Colon Diverticulosis. Korean J. Gastroenterol. 2019, 74, 142–148. [Google Scholar] [CrossRef] [Green Version]
Variable | Hepatic Steatosis | p-Value | ||
---|---|---|---|---|
Yes (n = 193) | No (n = 214) | Total (n = 407) | ||
Age, years (median, range) | 69 (36–89) | 67.5 (34–86) | 68 (34–89) | 0.166 |
Sex, male (n, %) | 101 (52.33) | 118 (55.14) | 219 (53.81) | 0.570 |
Fasting glucose, mmol/L (median, range) | 6.1 (2.4–15.9) | 5.45 (2.8–16.7) | 5.9 (2.4–16.7) | <0.001 |
Systolic blood pressure, mmHg (median, range) | 140 (80–240) | 140 (85–230) | 140 (80–240) | 0.036 |
Diastolic blood pressure, mmHg (median, range) | 90 (60–145) | 90 (45–145) | 90 (45–145) | 0.293 |
Tryglicerides, mmol/L (median, range) | 1.96 (0.5–6.67) | 1.7 (0.2–13) | 1.8 (0.2–13) | <0.001 |
HDL 1 cholesterol, mmol/L (median, range) | 1 (0.3–2.46) | 1.02 (0.2–2.3) | 1 (0.2–2.46) | 0.093 |
Total cholesterol, mmol/L (median, range) | 5.7 (1.18–9.8) | 4.8 (1.45–10) | 5.03 (1.18–10) | <0.001 |
CRP 2, mg/L (median, range) | 12 (0.1–418.5) | 5 (0.1–211) | 8 (0.1–418.5) | <0.001 |
Hypertension (yes/no, n (%)) | 149/44 (77.2/22.8) | 114/100 (53.27/46.73) | 263/144 (64.62/35.38) | <0.001 |
Diabetes mellitus type 2 (yes/no, n (%)) | 126/67 (65.28/34.72) | 95/119 (44.39/55.61) | 221/186 (54.3/45.7) | <0.001 |
Hypothyroidism (yes/no, n (%)) | 41/152 (21.24/78.76) | 24/190 (11.21/88.79) | 65/342 (15.97/84.03) | 0.008 |
AST 3, U/L (median, range) | 18 (8–187) | 15 (6–676) | 16 (6–676) | <0.001 |
ALT 4, U/L (median, range) | 18 (6–364) | 15 (7–259) | 17 (6–364) | 0.001 |
ALP 5, U/L (median, range) | 35 (9–401) | 18 (9–703) | 24 (9–703) | <0.001 |
GGT 6, U/L (median, range) | 26 (5–735) | 20 (8–1115) | 23 (5–1115) | 0.011 |
Chronic kidney disease, unspecified (yes/no, n (%)) | 9/184 (4.66/95.34) | 4/210 (1.87/98.13) | 13/394 (3.19/96.81) | 0.187 |
Characteristic | DICA Category 1 | p | |
---|---|---|---|
1 (n = 347) | 2 + 3 (n = 60) | ||
Age, years (median, range) | 68 (34–89) | 70 (45–86) | 0.343 |
Sex (male/female, n (%)) | 185/162 (53.31/46.69) | 34/26 (56.7/43.3) | 0.631 |
Fasting glucose, mmol/L (median, range) | 5.8 (2.4–16.7) | 6.09 (2.8–12.3) | 0.596 |
Systolic blood pressure, mmHg (median, range) | 140 (90–240) | 130 (80–190) | 0.335 |
Diastolic blood pressure, mmHg (median, range) | 90 (60–145) | 80 (45–100) | 0.196 |
Tryglicerides, mmol/L (median, range) | 1.8 (0.2–13) | 1.53 (0.50–5.26) | 0.244 |
HDL 2 cholesterol, mmol/L (median, range) | 1.01 (0.2–2.46) | 0.92 (0.30–1.86) | 0.006 |
Total cholesterol, mmol/L (median, range) | 5.03 (1.18–10) | 5.01 (1.45–9.20) | 0.769 |
CRP 3, mg/L (median, range) | 7 (0.1–418.5) | 14.95 (0.4–306.7) | 0.015 |
Hypertension (yes/no, n (%)) | 216/131 (62.3/37.7) | 47/13 (78.3/21.7) | 0.016 |
Diabetes mellitus type 2 (yes/no, n (%)) | 185/162 (53.3/46.7) | 36/24 (60.0/40.0) | 0.337 |
Hypothyroidism (yes/no, n (%)) | 56/291 (16.1/83.9) | 9/51 (15.0/85.0) | 0.824 |
AST 4, U/L (median, range) | 16 (6–676) | 16.5 (9–170) | 0.343 |
ALT 5, U/L (median, range) | 16 (6–364) | 18 (7–220) | 0.266 |
ALP 6, U/L (median, range) | 22 (9–703) | 33.5 (9–357) | 0.029 |
GGT 7, U/L (median, range) | 23 (5–1115) | 26.5 (7–735) | 0.318 |
Chronic kidney disease, unspecified (yes/no, n (%)) | 9/338 (2.59/97.41) | 4/56 (6.7–93.3) | 0.098 |
Variable | Hepatic Steatosis | p-Value | |
---|---|---|---|
Yes (n = 193) | No (n = 214) | ||
DICA 1 category | |||
1 (n, %) | 155 (80.31) | 192 (89.72) | 0.025 |
2 (n, %) | 33 (17.1) | 20 (9.35) | |
3 (n, %) | 5 (2.59) | 2 (0.93) | |
DICA score (median, range) | 3 (1–12) | 3 (1–11) | 0.004 |
Hemicolectomia | |||
Yes (n, %) | 3 (1.55) | 3 (1.4) | 1 |
No (n, %) | 190 (98.45) | 211 (98.6) |
Predictor | Univariate Logistic Regression | Multivariate Logistic Regression | ||||||
---|---|---|---|---|---|---|---|---|
B | OR | 95%CI OR | p | B | OR | 95%CI OR | p | |
DICA 1, points | 0.249 | 1.282 | 1.09–1.51 | 0.003 | 0.260 | 1.296 | 1.09–1.54 | 0.004 |
Hypertension, yes | 1.089 | 2.970 | 1.93–4.57 | <0.001 | 0.779 | 2.179 | 1.35–3.51 | 0.001 |
T2DM 2, yes | 0.857 | 1.356 | 1.58–3.52 | <0.001 | 0.400 | 1.492 | 0.95–2.35 | 0.083 |
Hypothyroidism, yes | 0.759 | 2.135 | 1.24–3.69 | 0.007 | 0.660 | 1.935 | 1.07–3.49 | 0.028 |
Total cholesterol | 0.369 | 1.447 | 1.27–1.65 | <0.001 | 0.340 | 1.404 | 1.20–1.64 | <0.001 |
Triglycerides | 0.318 | 1.374 | 1.14–1.65 | 0.001 | 0.092 | 1.096 | 0.89–1.35 | 0.381 |
C-reactive protein | 0.011 | 1.011 | 1.01–1.02 | 0.001 | 0.010 | 1.010 | 1.00–1.02 | 0.004 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Pantic, I.; Lugonja, S.; Rajovic, N.; Dumic, I.; Milovanovic, T. Colonic Diverticulosis and Non-Alcoholic Fatty Liver Disease: Is There a Connection? Medicina 2022, 58, 38. https://doi.org/10.3390/medicina58010038
Pantic I, Lugonja S, Rajovic N, Dumic I, Milovanovic T. Colonic Diverticulosis and Non-Alcoholic Fatty Liver Disease: Is There a Connection? Medicina. 2022; 58(1):38. https://doi.org/10.3390/medicina58010038
Chicago/Turabian StylePantic, Ivana, Sofija Lugonja, Nina Rajovic, Igor Dumic, and Tamara Milovanovic. 2022. "Colonic Diverticulosis and Non-Alcoholic Fatty Liver Disease: Is There a Connection?" Medicina 58, no. 1: 38. https://doi.org/10.3390/medicina58010038
APA StylePantic, I., Lugonja, S., Rajovic, N., Dumic, I., & Milovanovic, T. (2022). Colonic Diverticulosis and Non-Alcoholic Fatty Liver Disease: Is There a Connection? Medicina, 58(1), 38. https://doi.org/10.3390/medicina58010038